If you purchased or acquired securities in AstraZeneca between between February 23, 2022 and December 17, 2024 and would like ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn ...

The AstraZeneca PLC ADR AZN slipped 1.27% to $69.86 Monday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index COMP falling 1.20% to ...

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

AstraZeneca PLC closed 15.78% below its 52-week high of £133.88, which the company achieved on September 3rd.

AstraZeneca’s investments in Canada since 2023 now exceed $0.9bn, creating a total of 1,200 new high-skilled jobs. In 2024, ...

Flagship Harbor Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 2.5% during the 4th ...

AstraZeneca Plc abandoned plans to invest £450 million ($558 million) in a UK vaccine manufacturing plant, following protracted wrangling with the new Labour government over the level of state funding ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

AstraZeneca PLC (LON:AZN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the nine ratings firms that are currently covering the firm, Marketbeat.com reports.

(Alliance News) - AstraZeneca PLC on Monday said Imfinzi has been recommended for approval in the EU as monotherapy for limited-stage small cell lung cancer.